Bills Supporting Device Opioid Alternatives Advance In House
The House Energy and Commerce Committee approved four opioid crisis-related bills that call for US FDA meetings and consideration of streamlined pathways for medtech alternatives to opioids, and for a report and action by the US Medicare agency on overcoming payment challenges to device pain control products.
You may also be interested in...
A provision to expand Sunshine Act industry reporting requirements for companies in the Senate-passed “Opioid Crisis Response Act” has caught criticism from the device sector, despite overall industry support for the legislation.
Several bills that try to lift barriers to development and use of device alternatives for pain management in response to the opioid crisis were recently approved by the US House.
Senators on June 12 advanced a bill addressing the opioid crisis from the Finance Committee, including sunshine provisions expanding the types of providers that must report payments of value by drug and device manufacturers, requiring an essential Medicare handbook to describe non-opioid alternatives for pain control, and expanding telehealth payments for providers treating beneficiaries with substance use disorders.